{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:11Z","timestamp":1791353711870,"version":"4.3.1"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteosarcoma is the most frequent primary bone tumor that develops mainly in the young, the median age of diagnosis being 18 years. Despite improvement in osteosarcoma treatment, survival rate is only 30% at 5 years for patients with pulmonary metastases at diagnosis. This warrants exploration of new therapeutic options, and among them, osteoprotegerin (OPG), a naturally occurring protein that inhibits bone resorption, is very promising in blocking the vicious cycle between bone resorption and tumor proliferation that takes place during tumor development in bone site. As OPG binds and inhibits the activity of tumor necrosis factor\u2013related apoptosis-inducing ligand, the truncated form of murine OPG 1-194 was used. The cDNA encoding OPG was administered by gene transfer using replication-defective adenoviral vector or was associated with an amphiphilic polymer in two models of rodent osteosarcoma. In both models, OPG gene transfer was effective in preventing the formation of osteolytic lesions associated with osteosarcoma development, in reducing the tumor incidence and the local tumor growth, leading to a 4-fold augmentation of mice survival 28 days postimplantation. On the contrary, OPG did not prevent the development of pulmonary metastasis alone, suggesting that bone environment is necessary for OPG therapeutic efficacy. Because OPG has no direct activity on osteosarcoma cells in vitro (cell binding, cell proliferation, apoptosis, or cell cycle distribution), we show that OPG exerts indirect inhibitory effect on tumor progression through the inhibition of RANKL whose production is enhanced in bone tumor environment, leading to osteolysis inhibition as reflected by osteoclast number decrease. [Cancer Res 2007;67(15):7308\u201318]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4130","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T18:34:13Z","timestamp":1185993253000},"page":"7308-7318","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption"],"prefix":"10.1158","volume":"67","author":[{"given":"Franc\u0327ois","family":"Lamoureux","sequence":"first","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Richard","sequence":"additional","affiliation":[{"name":"3INSERM, U533,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Wittrant","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u0301verine","family":"Battaglia","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pilet","sequence":"additional","affiliation":[{"name":"4INSERM, U791, Centre Commun de Microscopie Electronique et de Microanalyse, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vale\u0301rie","family":"Trichet","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fre\u0301de\u0301ric","family":"Blanchard","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327ois","family":"Gouin","sequence":"additional","affiliation":[{"name":"5Service d'Orthope\u0301die, CHU Ho\u0302tel Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pitard","sequence":"additional","affiliation":[{"name":"3INSERM, U533,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327oise","family":"Redini","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale (INSERM), ERI 7,"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives, EA3822,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623341226500_B1","unstructured":"Bell W, Siegal GP. Osteosarcoma. In: Cullinane C, Burchill S, Squire J, Lewis I, O'Leary J, editors. Molecular biology and pathology of pediatric cancer. London, Oxford University Press; 2002."},{"key":"2022061623341226500_B2","doi-asserted-by":"crossref","unstructured":"Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr\u20082000; 10: 159\u201378.","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50"},{"key":"2022061623341226500_B3","doi-asserted-by":"crossref","unstructured":"Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Re\u0301dini F, Heymann D. The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev\u20082004; 15: 457\u201375.","DOI":"10.1016\/j.cytogfr.2004.06.004"},{"key":"2022061623341226500_B4","doi-asserted-by":"crossref","unstructured":"Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun\u20081998; 247: 610\u20135.","DOI":"10.1006\/bbrc.1998.8697"},{"key":"2022061623341226500_B5","doi-asserted-by":"crossref","unstructured":"Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev\u20081998; 12: 1260\u20138.","DOI":"10.1101\/gad.12.9.1260"},{"key":"2022061623341226500_B6","doi-asserted-by":"crossref","unstructured":"Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer\u20082001; 92: 460\u201370.","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D"},{"key":"2022061623341226500_B7","doi-asserted-by":"crossref","unstructured":"Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor \u03baB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol\u20082003; 163: 2021\u201331.","DOI":"10.1016\/S0002-9440(10)63560-2"},{"key":"2022061623341226500_B8","doi-asserted-by":"crossref","unstructured":"Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology\u20081999; 140: 4451\u20138.","DOI":"10.1210\/endo.140.10.7037"},{"key":"2022061623341226500_B9","doi-asserted-by":"crossref","unstructured":"Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol\u20082002; 198: 228\u201336.","DOI":"10.1002\/path.1199"},{"key":"2022061623341226500_B10","doi-asserted-by":"crossref","unstructured":"Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta\u20082004; 1704: 49\u201357.","DOI":"10.1016\/j.bbcan.2004.05.002"},{"key":"2022061623341226500_B11","doi-asserted-by":"crossref","unstructured":"Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood\u20082001; 98: 3534\u201340.","DOI":"10.1182\/blood.V98.13.3534"},{"key":"2022061623341226500_B12","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res\u20082001; 61: 4432\u20136."},{"key":"2022061623341226500_B13","doi-asserted-by":"crossref","unstructured":"Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature\u20082006; 440: 692\u20136.","DOI":"10.1038\/nature04524"},{"key":"2022061623341226500_B14","doi-asserted-by":"crossref","unstructured":"Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van HL, Lacey DL. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res\u20082000; 18: 967\u201376.","DOI":"10.1002\/jor.1100180617"},{"key":"2022061623341226500_B15","unstructured":"Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res\u20082001; 61: 4038\u201347."},{"key":"2022061623341226500_B16","unstructured":"Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant Osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res\u20082003; 63: 287\u20139."},{"key":"2022061623341226500_B17","unstructured":"Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice. Cancer Res\u20082003; 63: 2096\u2013102."},{"key":"2022061623341226500_B18","doi-asserted-by":"crossref","unstructured":"Bolon B, Carter C, Daris M, et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther\u20082001; 3: 197\u2013205.","DOI":"10.1006\/mthe.2001.0245"},{"key":"2022061623341226500_B19","doi-asserted-by":"crossref","unstructured":"Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther\u20082002; 13: 1767\u201375.","DOI":"10.1089\/104303402760293592"},{"key":"2022061623341226500_B20","doi-asserted-by":"crossref","unstructured":"Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA\/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res\u20082004; 32: e159.","DOI":"10.1093\/nar\/gnh153"},{"key":"2022061623341226500_B21","doi-asserted-by":"crossref","unstructured":"Desigaux L, Gourden C, Bello-Roufai M, et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther\u20082005; 16: 821\u20139.","DOI":"10.1089\/hum.2005.16.821"},{"key":"2022061623341226500_B22","doi-asserted-by":"crossref","unstructured":"Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther\u20082005; 16: 1318\u201324.","DOI":"10.1089\/hum.2005.16.1318"},{"key":"2022061623341226500_B23","doi-asserted-by":"crossref","unstructured":"Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett\u20082002; 188: 213\u20139.","DOI":"10.1016\/S0304-3835(02)00433-0"},{"key":"2022061623341226500_B24","doi-asserted-by":"crossref","unstructured":"Cherrier B, Gouin F, Heymann MF, et al. A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol\u20082005; 26: 121\u201330.","DOI":"10.1159\/000086483"},{"key":"2022061623341226500_B25","doi-asserted-by":"crossref","unstructured":"Yaffe D, Saxel O. A myogenic cell line with altered serum requirements for differentiation. Differentiation\u20081977; 7: 159\u201366.","DOI":"10.1111\/j.1432-0436.1977.tb01507.x"},{"key":"2022061623341226500_B26","doi-asserted-by":"crossref","unstructured":"Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol\u20082006; 28: 261\u20139.","DOI":"10.3892\/ijo.28.1.261"},{"key":"2022061623341226500_B27","doi-asserted-by":"crossref","unstructured":"He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A\u20081998; 95: 2509\u201314.","DOI":"10.1073\/pnas.95.5.2509"},{"key":"2022061623341226500_B28","unstructured":"Thie\u0301ry J-P, Perdereau B, Gongora R, Gongora G, Mazabraud A. Un mode\u0300le experimental d'oste\u0301osarcome chez le rat. II. L'oste\u0301osarcome greffable du rat. Sem Ho\u0302p Paris\u20081982; 58: 1686\u20139."},{"key":"2022061623341226500_B29","doi-asserted-by":"crossref","unstructured":"Pollard H, Remy S, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem\u20081998; 273: 7507\u201311.","DOI":"10.1074\/jbc.273.13.7507"},{"key":"2022061623341226500_B30","doi-asserted-by":"crossref","unstructured":"Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone\u20082005; 37: 74\u201386.","DOI":"10.1016\/j.bone.2005.02.020"},{"key":"2022061623341226500_B31","doi-asserted-by":"crossref","unstructured":"Alatalo SL, Halleen JM, Hentunen TA, Mo\u0308nkko\u0308nen J, Va\u0308a\u0308na\u0308nen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem\u20082000; 46: 1751\u201354.","DOI":"10.1093\/clinchem\/46.11.1751"},{"key":"2022061623341226500_B32","doi-asserted-by":"crossref","unstructured":"Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis\u20082003; 41: 1052\u201359.","DOI":"10.1016\/S0272-6386(03)00203-8"},{"key":"2022061623341226500_B33","unstructured":"Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res\u20082000; 60: 783\u20137."},{"key":"2022061623341226500_B34","doi-asserted-by":"crossref","unstructured":"Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest\u20082001; 107: 1235\u201344.","DOI":"10.1172\/JCI11685"},{"key":"2022061623341226500_B35","doi-asserted-by":"crossref","unstructured":"Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem\u20081998; 273: 14363\u20137.","DOI":"10.1074\/jbc.273.23.14363"},{"key":"2022061623341226500_B36","doi-asserted-by":"crossref","unstructured":"Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci\u20082006; 110: 279\u201391.","DOI":"10.1042\/CS20050175"},{"key":"2022061623341226500_B37","doi-asserted-by":"crossref","unstructured":"Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res\u20082006; 66: 3620\u20138.","DOI":"10.1158\/0008-5472.CAN-05-3119"},{"key":"2022061623341226500_B38","doi-asserted-by":"crossref","unstructured":"Kostenuik PJ, Bolon B, Morony S, et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone\u20082004; 34: 656\u201364.","DOI":"10.1016\/j.bone.2003.12.006"},{"key":"2022061623341226500_B39","doi-asserted-by":"crossref","unstructured":"Yang SY, Mayton L, Wu B, Goater JJ, Schwartz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum\u20082002; 46: 2514\u201323.","DOI":"10.1002\/art.10527"},{"key":"2022061623341226500_B40","doi-asserted-by":"crossref","unstructured":"Atkins GJ, Bouralexis S, Haynes DR, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumor of bone. Bone\u20082001; 28: 370\u20137.","DOI":"10.1016\/S8756-3282(01)00404-5"},{"key":"2022061623341226500_B41","doi-asserted-by":"crossref","unstructured":"Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Met\u20082004; 21: 381\u20137.","DOI":"10.1007\/s10585-004-2869-0"},{"key":"2022061623341226500_B42","doi-asserted-by":"crossref","unstructured":"Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res\u20082005; 65: 1710\u20138.","DOI":"10.1158\/0008-5472.CAN-04-2033"},{"key":"2022061623341226500_B43","doi-asserted-by":"crossref","unstructured":"Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun\u20082000; 267: 632\u20137.","DOI":"10.1006\/bbrc.1999.2008"},{"key":"2022061623341226500_B44","doi-asserted-by":"crossref","unstructured":"Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res\u20082007; 67: 202\u20139.","DOI":"10.1158\/0008-5472.CAN-06-1287"},{"key":"2022061623341226500_B45","doi-asserted-by":"crossref","unstructured":"Paget S. The distrubution of secondary growths in cancer of the breast. Lancet\u20081889; 1: 571\u20132.","DOI":"10.1016\/S0140-6736(00)49915-0"},{"key":"2022061623341226500_B46","unstructured":"Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact\u20082004; 4: 308\u201318."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7308\/2865393\/7308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7308\/2865393\/7308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:48:22Z","timestamp":1655437702000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7308\/533328\/Therapeutic-Relevance-of-Osteoprotegerin-Gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":46,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4130","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}